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ABSTRACT
The use of a combination inhaler containing budesonide
and formoterol as both maintenance and quick relief
therapy (SMART) has been recommended as an
improved method of using inhaled corticosteroid/long-
acting b agonist (ICS/LABA) therapy. Published double-
blind trials show that budesonide/formoterol therapy
delivered in SMART fashion achieves better asthma
outcomes than budesonide monotherapy or lower doses
of budesonide/formoterol therapy delivered in constant
dosage. Attempts to compare budesonide/formoterol
SMART therapy with regular combination ICS/LABA
dosing using other compounds have been confounded by
a lack of blinding and unspecified dose adjustment
strategies. The asthma control outcomes in SMART-
treated patients are poor; it has been reported that only
17.1% of SMART-treated patients are controlled. In
seven trials of 6e12 months duration, patients using
SMART have used quick reliever daily (weighted average
0.92 inhalations/day), have awakened with asthma
symptoms once every 7e10 days (weighted average
11.5% of nights), have suffered asthma symptoms more
than half of days (weighted average 54.0% of days) and
have had a severe exacerbation rate of one in five
patients per year (weighted average 0.22 severe
exacerbations/patient/year). These poor outcomes may
reflect the recruitment of a skewed patient population.
Although improvement from baseline has been attributed
to these patients receiving additional ICS therapy at
pivotal times, electronic monitoring has not been used to
test this hypothesis nor the equally plausible hypothesis
that patients who are non-compliant with maintenance
medication have used budesonide/formoterol as needed
for self-treatment of exacerbations. Although the long-
term consequences of SMART therapy have not been
studied, its use over 1 year has been associated with
significant increases in sputum and biopsy eosinophilia.
At present, there is no evidence that better asthma
treatment outcomes can be obtained by moment-to-
moment symptom-driven use of ICS/LABA therapy than
conventional physician-monitored and adjusted ICS/LABA
therapy.
INTRODUCTION
For patients whose asthma remains uncontrolled
despite the regular inhalation of corticosteroid
alone, the inhalation of corticosteroid coupled with
long-acting b2 agonist (ICS/LABA) from a single
inhalation device twice daily has become a valuable
strategy.1 This combination approach reduces
exacerbation risk and increases the likelihood of
controlling asthma more often, more rapidly and at
a lower dose of ICS than is seen with ICS therapy
alone.2e4 Typically, combination ICS/LABA
therapy has been prescribed with a separate rapid-
acting b agonist inhaler used for relief of occasional
breakthrough symptoms, but combination ICS/
LABA formulations employing formoterol as the
LABA component allow patients to employ their
usual maintenance inhaler for quick relief as well.
This strategy of medication use has been recognised
by regulatory authorities and in international
guidelines.1 It has recently been argued that
a strategy of using single maintenance and reliever
therapy (SMART) offers more than convenience to
patients; it is said to provide better improvements
in several outcomes with lower ICS dosing than the
traditional combination therapy approach of
constant maintenance dosing with a separate
reliever.5e7 Since these recommendations were
made, the SMART strategy studies have been
reviewed critically and independently as part of the
Cochrane process, the impact of SMART therapy
upon airways inﬂammation has been reported and
the limitations of the research evidence have been
highlighted.8 9 Given these emerging concerns, the
following review examines critically the studies
that have tested the SMART strategy to determine
the strength of evidence supporting its potential
beneﬁts, its applicability to the general asthma
population and the questions that remain
unanswered.
CLINICAL STUDIES
Double-blind studies
Three double-blind studies explored the SMART
strategy in ICS-treated but poorly controlled
patients.10e12 These studies compared SMART
with conventional ICS monotherapy with bude-
sonide alone or, in one study, with conventional
combination therapy with budesonide/formoterol
and a separate short-acting b agonist (SABA)
reliever (ﬁgure 1).
Rabe and colleagues assigned patients to
6 months of either budesonide/formoterol combi-
nation inhaler (Symbicort 100/6) one puff twice
daily and as needed up to 10 puffs per day or
budesonide 200 mg (Pulmicort) one puff twice daily
with terbutaline 500 mg/puff (Bricanyl) as needed.10
In contrast to almost all subsequent SMART
studies, the primary outcome variable was
a measure of lung function rather than time to ﬁrst
severe exacerbation. Morning peak expiratory ﬂow
(PEF) improved signiﬁcantly more in patients
treated with ICS/LABA than in those treated with
ICS alone. Other outcome variables similarly
favoured the ICS/LABA group including evening
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PEF, reliever-free days, as-needed reliever use, asthma symptom
score, symptom-free days and asthma control days. Also noted
was a reduced ‘severe’ exacerbation rate in patients treated with
ICS/LABA. The deﬁnition of severe exacerbation was expanded
in this study beyond the usual clinical meaning to include not
only a hospitalisation or emergency department visit but also
a short course of prednisone or a decrease in morning PEF $30%
from baseline on two or more consecutive days. Indeed, 57 of 66
exacerbations deﬁned by the fall in morning PEF had not been
detected clinically by the patient or investigator. Deﬁning an
exacerbation based solely on PEF changes has been questioned in
a recent review and the ATS/ERS statement concerning the
deﬁnition of exacerbations for asthma research.13 The pattern of
reliever use was examined in the SMART group; despite 6% of
patients using >8 puffs of ICS/LABA as reliever at least once
during the trial and 3% using >10 puffs on at least one day, no
adverse events were attributed to such usage although three
episodes of tachycardia were reported in the SMART group and
none in the budesonide monotherapy group. Other safety
parameters were not signiﬁcantly different between groups.
Scicchitano and colleagues undertook a study of similar design
to the study by Rabe et al but the study was of 12 months
duration and time to ﬁrst severe exacerbation (using the
expanded deﬁnition) was the primary outcome variable.11 One
arm was treated with budesonide/formoterol 200/6 (Symbicort
200/6) once daily with additional doses as needed, the other
received budesonide 200 mg (Pulmicort 200) two puffs twice
daily with terbutaline 500 mg/puff reliever as needed. The results
were similar to those reported by Rabe and colleagues. Time to
ﬁrst severe exacerbation was longer in the ICS/LABA combina-
tion therapy group while other symptom outcomes were also
better. Most adverse events and safety events were similar
between treatment groups, although one patient in the SMART
group developed atrial ﬁbrillation attributed to study medication
by the investigator.
The results of these two early SMART trials do not elucidate
a unique value of a SMARTapproach; they conﬁrm only that the
addition of a long-acting b2 agonist to inhaled steroids is an
effective option.
The largest of the early trials was reported by O’Byrne and
colleagues.12 This 1-year trial assigned patients to (1) budeso-
nide/formoterol 100/6 one puff twice daily with terbutaline
reliever; (2) budesonide 400 mg twice daily with terbutaline
reliever; or (3) budesonide/formoterol 100/6 one puff twice daily
with additional doses as reliever. Time to ﬁrst severe exacerba-
tion was delayed in the SMART group compared with the other
regimens. Secondary outcome variables were also better. The
investigators suggested the timing of additional ICS therapy in
the SMART group as a possible mechanism to explain the better
outcomes with SMART versus budesonide monotherapy at
mean daily doses of 300 mg versus 400 mg respectively. They did
not discuss the improved outcome of SMART versus conven-
tional combination therapy with SABA reliever, but their data
showed that patients on SMARTaveraged 50% higher daily ICS
doses than patients using conventional combination therapy.
Thus, this trial reconﬁrms that increasing the dose of ICS may
be helpful in improving asthma outcomes.
A later blinded trial by Rabe and colleagues compared two
conventional combination treatment arms with a SMART
treatment arm over 12 months (ﬁgure 1).14 Patients with poorly
controlled asthma were randomised to budesonide/formoterol
200/6 (Symbicort 200) one puff twice daily and one of terbu-
taline 500 mg, formoterol 6 mg or budesonide/formoterol 200/6 as
reliever. The time to ﬁrst severe exacerbation (deﬁned as hospi-
talisation, emergency department visit or prednisone use) was
longest in the SMART arm, shorter in the formoterol reliever
arm and shortest in the terbutaline reliever arm. Although
several individual symptom outcomes were statistically better in
the SMART arm than in the comparator arms, there was no
difference among treatments in the asthma control days or the
Figure 1 Study designs for double-blind single maintenance and reliever therapy (SMART) studies. (A) Comparison of inhaled corticosteroid (ICS)
monotherapy with ICS/long-acting b agonist (LABA).15 (B) Comparison of ICS monotherapy with ICS/LABA.16 (C) Comparison of ICS monotherapy with
two doses of ICS/LABA, SMART being the higher dosage ICS/LABA treatment arm.17 (D) Comparison of three ICS/LABA treatment arms: with short-
acting b2 agonist, with additional LABA or with additional ICS and additional LABA.
19 BUD, budesonide; FORM, formoterol.
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quality of life. The average daily dose of budesonide was
increased by 50% in the SMART-treated patients compared with
the comparator arms (604 mg vs 400 mg).
In aggregate, these blinded studies showed no clear safety
signals for SMART therapy. They conﬁrmed that combination
therapy with ICS/LABA produces better asthma outcomes than
ICS monotherapy and that higher doses of ICS/LABA combi-
nation therapy produces better results than lower doses.
Comparative studies
Several studies have compared SMART with budesonide/
formoterol with conventional combination therapy with
salmeterol/ﬂuticasone. Such studies have been confounded by
a lack of blinding and several elements of trial design that subtly
disadvantaged the non-SMART arm. For example, Vogelmeier
and colleagues reported fewer severe exacerbations in patients
treated with budesonide/formoterol in SMART fashion
compared with patients treated with ﬂuticasone/salmeterol and
separate salbutamol reliever.15 However, the authors acknowl-
edged that ‘as titration of maintenance medication was left to
physician judgement and was not protocol driven, patients
could have been inadvertently undertreated’. A majority of
patients (62%) were using budesonide (most likely in Turbuhaler
format) at the time of recruitment; it would be difﬁcult to
exclude bias in the study with patients assigned to their familiar
inhaler or a novel inhaler in open-label fashion. The use of
devices that require different inhalation techniques (dry powder
Turbuhaler SMARTarm versus metered dose aerosol comparator
arm) further complicates interpretation. Moreover, the investi-
gators chose to report the doses of inhaled medication differ-
ently between arms, using lower ex-actuator values for the
SMARTarm and higher ex-valve values for the comparator arm.
Although this and several other studies have suggested lower
ICS exposure for patients using a SMART regimen, this
conclusion has been based on patient diary reports of medication
use and has not been validated by demonstrating differences in
urinary cortisol values or other pharmacodynamic end points.
Sears et al have also reported a study in which the manage-
ment of the comparator arm was undeﬁned.16 Patients with
poorly controlled asthma were recruited from community
practices. Some participating practices were asked to instruct
patients in the correct use of a Turbuhaler and to switch these
patients to SMART therapy while other practices were left to
manage patients using ‘current best practice’, a strategy that
was unspeciﬁed. Despite failing to show signiﬁcant differences
between treatments in the primary outcome variable (time to
ﬁrst severe exacerbation) and almost all secondary outcome
variables (including hospitalisation rates, emergency department
visits, PEF, Asthma Control Questionnaire (ACQ)-5 and sputum
eosinophil counts), the investigators calculated the lower
medication costs in the SMART group and reported the statis-
tical signiﬁcance of the ﬁnding. Similar negative ﬁndings (but
without sputum eosinophil assessment) are available online
from two unpublished European studies.17 18
In a blinded study, Bousquet and colleagues also failed to ﬁnd
a signiﬁcant difference between budesonide/formoterol SMART
therapy and constant dose ﬂuticasone/salmeterol therapy in
their primary outcome variable, time to ﬁrst severe exacerbation
and multiple secondary outcomes including reliever use,
percentage of reliever-free days, asthma symptom scores,
percentage of symptom-free days, nocturnal awakenings,
asthma control days, ACQ-5 and morning and evening PEF.19
Time to ﬁrst plus second exacerbations was signiﬁcantly lower in
the budesonide/formoterol group than in the ﬂuticasone/
salmeterol group. This study differed from others in attempting
to double-blind the study using double dummy techniques,
although it seems probable that patients would have been able
to distinguish bronchodilator-containing inhalers from placebo
inhalers. Terbutaline was the reliever medication in the non-
SMART arm rather than formoterol, an important difference
given the different efﬁcacy and side effect proﬁles between these
bronchodilators. Two other studies have compared the as-needed
use of these two bronchodilators in a population of patients
with asthma characteristics similar to those in the study by
Bousquet et al and reported a signiﬁcantly delayed time to ﬁrst
severe exacerbation in the formoterol-treated arm.14 20 Both
found a signiﬁcant delay in time to ﬁrst exacerbation for
formoterol compared with terbutaline as rescue medication. In
addition, the regular use of the short-acting terbutaline has been
associated with increased bronchial hyper-reactivity and airways
inﬂammation.21 22 Thus, some of the ﬁndings in the study by
Bousquet et al might as plausibly be attributed to the pharma-
cological differences between as-needed bronchodilators as to
the differences in combination strategies. A study by Kuna and
colleagues comparing salmeterol/ﬂuticasone plus terbutaline,
budesonide/formoterol plus terbutaline and SMART was simi-
larly confounded.23 Moreover, the patients in the salmeterol/
ﬂuticasone arm of that study used two different delivery
systems (a pressurised aerosol inhaler and a dry powder inhaler),
a potential factor in the results seen.
A recent Cochrane analysis of the ﬁndings in these studies
concluded that ‘. [SMART] can reduce the risk of asthma
exacerbations needing oral corticosteroids in comparison with
ﬁxed dose maintenance inhaled corticosteroids . [SMART] has
not been demonstrated to signiﬁcantly reduce exacerbations in
comparison with current best practice’.8
Level of asthma control achieved with SMART
The goals of asthma management have evolved. The prevention
of asthma death, acute hospitalisations or shortening the dura-
tion of an acute asthma episode in the emergency department
are no longer regarded as sufﬁcient treatment targets. The main
focus is now on achievement of daily control and prevention of
the consequences of insufﬁcient daily control such as severe
medical crises and day-to-day disability.1 4 Patients with asthma
should be controlled so that they have few or no daytime
symptoms, no night-time symptoms, rare need for acute bron-
chodilator relief, no physical limitations, few or no exacerbations
and no absences from usual activities caused by asthma. The
SMART trials have reported mean results for each of these
outcomes separately rather than reporting the number of
patients achieving control, deﬁned by attaining an adequate
composite score of outcome variables. A composite score is
a more rigorous and discriminating evaluation of control than
any single symptom parameter and has been recommended in
the recent ATS/ERS statement concerning the evaluation of
control in clinical practice and clinical trials.13 24e26 Only
recently has the attainment of asthma control been reported for
SMART-treated patients. In a retrospective analysis of ﬁve
trials,10e12 19 23 Bateman and colleagues reported that, by the
last week of the study period (6e12 months), only 17.1% of
study patients were considered controlled according to Global
Initiative for Asthma (GINA) criteria.27 The remaining patients
were either partly controlled (38.7%) or uncontrolled (44.2%).
Among all trial patients, the risk of exacerbation was approxi-
mately twice as high for a partly-controlled versus a controlled
patient and almost six times as high for an uncontrolled versus
controlled patient.
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The results from the individual asthma control outcomes in the
SMARTstudies are summarised in table 1 andare consistent across
studies. On average, patients using SMART have used quick
reliever once per day, have awakenedwith asthma symptoms once
every 7e10 days, enjoyed freedom from asthma symptoms on
fewer than half of the days and experienced a severe exacerbation
rate of approximately one in ﬁve patients per year (this last ﬁgure,
expressed as the inverse of the annual rate of exacerbations per
subject given in table 1, will slightly overestimate the numbers of
patients affected because some patients suffered more than one
exacerbation during the trial). The largest effect of treatment is on
exacerbations,which have been reduced by around 50% compared
with comparator arms. The effect on the daily control parameters
has been much smaller. The data are reported as mean values for
the individual outcomes, so until recently it has not been known if
a subset of very unstable patients has driven these results or in
howmany patients guideline-deﬁned well-controlled disease was
achieved. Consistent with this lack of day-to-day asthma control,
SMART studies have not typically reported improvements in
health status or quality of life relative to baseline or to comparator
regimens. This is remarkable given the putative beneﬁt of severe
exacerbation reduction, an outcomeof considerable importance to
patients.28 29
Compliance
It has been suggested that the SMART strategy provides greater
clinical efﬁcacy at lower doses of ICS than the traditional
combination regimens, and that the corticosteroid works more
effectively when inhaled at the onset of exacerbations following
the onset of symptoms rather than preventively.30 These
suggestions have been based on diary card records of medication
use in the SMART trials but have not been validated by the use
of objective measurements. Poor compliance with inhaled
therapy is well documented and appears, at least in some
studies, to be no better in clinical trials than in routine clinical
care environments.31 Patients in trials have been reported to hide
their non-compliance from investigators; in the ﬁrst Lung
Health Study, the phenomenon of ‘dose-dumping’ in patients
was detected in 30% by the end of the trial and the suboptimal
compliance was not detectable by diary card record or canister
weighing.32 33 Electronic monitoring of dry powder devices
including the Turbuhaler is available and studies using such
monitoring have been reported. For example, Bosley and
colleagues used this technique to assess the impact on compli-
ance of combining a bronchodilator with an inhaled steroid.34
The treatment was taken as prescribed on only 30e40% of days,
with no evidence that compliance was enhanced by the addition
of terbutaline to budesonide. The authors concluded that
compliance appears to be a patient-dependent rather than
a drug-dependent issue.
In the SMART studies, patients have been recruited for their
pattern of poorly controlled asthma despite treatment with ICS
(with or without LABA). It is therefore possible that the persis-
tence of poor day-to-day symptom control on SMART treatment,
together with an apparent reduction in the need to seek medical
attention for severe exacerbations, is the consequence of poorly
compliant patients remaining poorly compliantwith their day-to-
day maintenance therapy but resorting to rescue combination
therapy for the self-treatment of exacerbations. Further studies
using objective monitoring of compliance are needed.
UNANSWERED QUESTIONS
Importance of symptom perception
SMART relies on a close association between bronchodilator use
and the underlying level of asthma control. However, this rela-
tionship is known to be imperfect. Patients often choose not to
use bronchodilator to relieve symptoms; asthma control indices
enumerate as separate parameters the frequency of daytime or
night-time symptoms and the frequency of reliever use for this
reason. Some patients with asthma may be particularly insen-
sitive to the perception of airway narrowing and the need to use
bronchodilator. Rubinﬁeld and Pain documented the phenom-
enon of the ‘poor perceiver ’, ﬁnding that one in seven of their
patients was unable to perceive a decrease in forced expiratory
volume in 1 s to <50% of predicted during methacholine chal-
lenge.35 Later investigations have identiﬁed patients who appear
‘hypersensitive’ to very small changes in airway calibre and may
use their bronchodilator too frequently.36 37 In agreement with
these ﬁndings, a poor correlation between measured airﬂow and
as-needed bronchodilator use has been reported in patients with
asthma; patterns of overuse and underuse of bronchodilator
predominate with only a minority using bronchodilator appro-
priately.38 Misuse was linked to high anxiety scores on the
Minnesota Multiphasic Personality Inventory. More studies are
needed to assess the importance of these problems on the effect
on symptom-driven maintenance therapy.
Long-term outcomes
A recent study has reported increased airways inﬂammation
among patients transitioning from conventional ﬁxed dose
Table 1 Asthma control end points, baseline and during SMART therapy
Rabe
et al10
Scicchitano
et al11
O’Byrne
et al 12
Rabe
et al14
Vogelmeier
et al15
Kuna
et al21
Bousquet
et al19
Weighted
averages
N (SMART arm) 354 947 925 1107 1067 1052 1151
Study duration 6 months 12 months 12 months 12 months 12 months 6 months 6 months N/A
Symptom-free days (%) B: 29.6 B: 9.8 B: 23.1 B: 9.2* NA B: 9.3 B: 10.7 B: 13.2
T: 55.1 T: 41.7 T: 54 T: 40.3* T: 44.2 T: 47.2 T: 46.0
As-needed reliever use
inhalations/day)
B: 1.64 B: 1.9 B: 2.46 B: 1.8 B: 2.6 B: 2.29 B: 2.23 B: 2.18
T: 1.04 T: 0.90 T: 1.01 T: 1.02 T: 0.59y T: 1.02 T: 0.95 T: 0.92
Reliever-free days (%) B: 24.3 B: 29.3 B: 8.2 B: N/A NA B: 8.9 B: 10.3 B: 14.7
T: 55.3 T: 59.8 T: 55 T: 52 T: 56 T: 58.2 T: 56.1
Nights with awakenings (%) B: 13.3 B: 22.6 B: 21.8 B: 31.1 NA B: 33.7 B: 32.1 B: 27.7
T: 6.5 T: 9.4 T: 9.0 T: 14.1 T: 14.1 T: 12.0 T: 11.5
Severe exacerbations
(events/patient/year)
0.08 0.23 0.19 0.19 0.24 0.24 0.25 0.22
*24-hour period.
yFor weeks 0e4 (during which morning and evening budesonide/formoterol doses were unchanged at two inhalations of 200/6).
B, baseline; T, treatment; NA, not available; N/A, not applicable; SMART, single maintenance and reliever therapy.
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maintenance therapy (when patients were receiving an average
of 804 mg ICS per day) to SMART therapy for 1 year prescribed
as 200/6 mg budesonide/formoterol twice daily plus as-needed
doses.9 In SMART-treated patients whose daily dose of bude-
sonide averaged 604 mg per day, eosinophil numbers rose signif-
icantly in bronchial biopsies compared with baseline (see ﬁgure 2).
In control patients who were randomised to a conventional
maintenance regimen of constant dose 800/12 mg budesonide/
formoterol twice daily with a separate SABA reliever, sputum
eosinophil counts fell and in biopsy specimens both eosinophil
and mast cell numbers fell signiﬁcantly.
Evaluating outcomes and action planning
The prescription of the SMART strategy does not obviate the
need to monitor and adjust maintenance medications, nor does
it obviate the need for action plans that would permit early self-
treatment of severe exacerbations requiring prednisone or
equivalent. However, it is unclear from the literature on SMART
which treatment outcomes best identify when the treatment
should be modiﬁed. By protocol, patients employing SMART
therapy are allowed to use additional budesonide/formoterol
inhaler up to eight puffs per day to relieve symptoms. Presum-
ably, if as-needed doses are needed persistently, the treatment is
deemed inadequate and the maintenance adjusted. However, the
exact level and duration of as-needed use at which dosage
adjustments should be made are not known. In the study by
Vogelmeier et al, two different maintenance doses of budesonide/
formoterol were permitted but the protocol for dosage adjust-
ment was not speciﬁed and appears to have been at the discre-
tion of the investigators.15
All studies with SMART have been conducted in patients
with uncontrolled asthma. The potential beneﬁts in partially
controlled asthma have not been assessed, and it seems unlikely
that there would be any beneﬁts of this regimen in controlled
patients who will use as-needed bronchodilator infrequently or
not at all. Indeed, this highlights the conundrum posed by the
SMARTstrategy; it is deﬁned by the use of as-needed medication
but the frequent use of as-needed medication is inconsistent
with our current deﬁnitions of control.
CONCLUSIONS
Published double-blind studies have shown that budesonide/
formoterol given in the SMART regimen is more effective than
budesonide alone or than lower doses of budesonide/formoterol
given in conventional fashion. It is still unclear how SMART
compares with guideline-recommended amounts of combina-
tion therapy taken preventively to minimise symptoms and
avoid reliever need. Guideline-recommended asthma control is
rarely achieved in published SMART trials, in contrast with the
reported reduction of severe exacerbations. Future studies should
assess which outcomes are most useful in deciding treatment
adjustments for patients inadequately controlled with the
strategy. The ﬁnding of increased eosinophilic airways inﬂam-
mation over 1 year of treatment is of concern and calls for
further long-term studies assessing inﬂammation and remodel-
ling. The recruitment of poorly controlled patients with
a history of recent exacerbations despite usually effective inhaled
therapy may skew the results of published SMART trials and
limit their application to a more typical asthma population.
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